The Economist 20260718 Trillion-dollar Lilly Summary
Generated by Codex with GPT 5.6 Sol XHigh
Eli Lilly has become the first pharmaceutical company valued above \$1trn, a status usually reserved for technology giants. Its rise rests largely on Zepbound and other GLP-1 medicines, which have turned obesity treatment into one of the industry’s biggest new markets. Yet chief executive Dave Ricks is using that success to pursue a broader ambition: remaking Lilly from a conventional drugmaker into a company built around prevention, direct relationships with patients and reusable technological platforms.
Continue ...